8-K Announcements
6Material company update
Mar 9, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Dec 18, 2025·SEC
Vera Therapeutics, Inc.(VERA)Earnings, Financials & Key Ratios
VERA•NASDAQ
$36.60
$2.62B mkt cap·Price updated May 6, 2026
AboutVera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.Show more
- Revenue$0
- EBITDA-$315M-88.6%
- Net Income-$300M-96.9%
- EPS (Diluted)-4.66-69.5%
- ROE-50.71%-13.1%
- ROIC-54.63%-41.4%
- Debt/Equity0.13+35.1%
- Interest Coverage-38.78-104.7%
VERA Key Insights
Vera Therapeutics, Inc. (VERA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 41.2% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 16.1% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
VERA Price & Volume
Vera Therapeutics, Inc. (VERA) stock price & volume — 10-year historical chart
Loading chart...
VERA Growth Metrics
Vera Therapeutics, Inc. (VERA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-96.92%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-61.81%
Return on Capital
10 Years-110.02%
5 Years-64.63%
3 Years-56.51%
Last Year-48.11%
VERA Recent Earnings
Vera Therapeutics, Inc. (VERA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)
Q1 2026Latest
Feb 26, 2026EPS
$1.39
Est $1.34
-3.7%
Revenue
—
Q4 2025
Nov 5, 2025EPS
$1.26
Est $1.20
-5.0%
Revenue
—
Q3 2025
Aug 5, 2025EPS
$1.20
Est $0.82
-46.3%
Revenue
—
Q2 2025
May 6, 2025EPS
$0.81
Est $0.75
-8.0%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $1.39vs $1.34-3.7% | — |
| Q4 2025 | Nov 5, 2025 | $1.26vs $1.20-5.0% | — |
| Q3 2025 | Aug 5, 2025 | $1.20vs $0.82-46.3% | — |
| Q2 2025 | May 6, 2025 | $0.81vs $0.75-8.0% | — |
Based on last 12 quarters of dataView full earnings history →
VERA Peer Comparison
Vera Therapeutics, Inc. (VERA) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CLDX | 2.29B | 34.39 | -8.82 | -78.63% | -172.53% | -49.09% | 0.00 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 VKTX | 3.74B | 32.28 | -10.12 | -71.31% | 0.00 | |||
 ARWR | 11.08B | 79.14 | -6486.89 | 232.58% | 18.54% | 35.64% | 0.73 | |
 KALV | 1.37B | 26.72 | -7.24 | -13.91% | -282.01% | 0.07 | ||
 BCAX | 1.3B | 23.78 | -19.02 | -30.17% | 0.00 | |||
 IDYA | 2.52B | 28.74 | -22.45 | 30.24% | -62.17% | -13.96% | 0.03 |
Compare VERA vs Peers
Vera Therapeutics, Inc. (VERA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VERA Income Statement
Vera Therapeutics, Inc. (VERA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 509K | 251K | 0 | -846K | 0 | 0 | 468K |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -509K▲ 0% | -251K▲ 50.7% | 0▲ 100.0% | 846K▲ 0% | 0▼ 100.0% | 0▲ 0% | -468K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | 50.69% | 100% | - | -100% | - | - |
| Operating Expenses | 11.7M | 47.81M | 34.4M | 91.75M | 102.01M | 167.17M | 315.47M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 4.41M | 3.89M | 11.92M | 21.91M | 23.79M | 41M | 100.22M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 7.29M | 43.92M | 22.48M | 69.84M | 78.22M | 126.17M | 215.26M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -11.96M▲ 0% | -48.06M▼ 301.8% | -34.4M▲ 28.4% | -90.9M▼ 164.2% | -102.01M▼ 12.2% | -167.17M▼ 63.9% | -315.47M▼ 88.7% |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -301.81% | 28.42% | -164.24% | -12.22% | -63.87% | -88.71% |
| EBITDA | -11.45M | -47.81M | -34.23M | -91.75M | -101.99M | -167.06M | -315M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -317.47% | 28.41% | -168.07% | -11.16% | -63.8% | -88.55% |
| D&A (Non-Cash Add-back) | 509K | 251K | 176K | -846K | 21K | 105K | 468K |
| EBIT | -11.8M | -53.25M | -32.59M | -88.06M | -92.2M | -144.52M | -292.08M |
| Net Interest Income | 108K | -158K | -5K | 758K | 4.19M | 13.09M | 16.95M |
| Interest Income | 159K | 8K | 15K | 1.75M | 7.98M | 20.71M | 24.48M |
| Interest Expense | 51K | 166K | 20K | 992K | 3.79M | 7.63M | 7.53M |
| Other Income/Expense | 108K | -5.35M | 1.79M | 1.85M | 6.02M | 15.02M | 15.86M |
| Pretax Income | -11.85M▲ 0% | -53.41M▼ 350.6% | -32.61M▲ 39.0% | -89.06M▼ 173.1% | -95.99M▼ 7.8% | -152.15M▼ 58.5% | -299.62M▼ 96.9% |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 1K | 1K | 1K | 1K | 1K | 1K | -1K |
| Effective Tax Rate % | -0.01% | -0% | -0% | -0% | -0% | -0% | 0% |
| Net Income | -11.85M▲ 0% | -53.41M▼ 350.6% | -32.61M▲ 38.9% | -89.06M▼ 173.1% | -95.99M▼ 7.8% | -152.15M▼ 58.5% | -299.62M▼ 96.9% |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -350.59% | 38.95% | -173.1% | -7.79% | -58.5% | -96.92% |
| Net Income (Continuing) | -11.85M | -53.41M | -32.61M | -89.06M | -95.99M | -152.15M | -299.62M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.46▲ 0% | -14.40▼ 316.2% | -2.43▲ 83.1% | -3.35▼ 37.9% | -2.25▲ 32.8% | -2.75▼ 22.2% | -4.66▼ 69.5% |
| EPS Growth % | - | -316.19% | 83.13% | -37.86% | 32.84% | -22.22% | -69.45% |
| EPS (Basic) | -3.46 | -14.40 | -2.43 | -3.35 | -2.25 | -2.75 | -4.66 |
| Diluted Shares Outstanding | 3.42M | 3.71M | 13.44M | 26.57M | 42.71M | 55.33M | 64.23M |
| Basic Shares Outstanding | 3.42M | 3.71M | 13.44M | 26.57M | 42.71M | 55.33M | 64.23M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
VERA Balance Sheet
Vera Therapeutics, Inc. (VERA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 3.56M | 54.26M | 82.54M | 125.7M | 172.02M | 651.22M | 728.88M |
| Cash & Short-Term Investments | 3.19M | 53.65M | 79.67M | 114.65M | 160.72M | 640.85M | 714.59M |
| Cash Only | 3.19M | 53.65M | 79.67M | 43.46M | 45.68M | 92.65M | 354.73M |
| Short-Term Investments | 0 | 0 | 0 | 71.19M | 115.03M | 548.21M | 359.86M |
| Accounts Receivable | 0 | 52K | 0 | 0 | 0 | 3.77M | 3.29M |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 4K | 442K | 480K | 719K | 3.22M | 913K | 11.01M |
| Total Non-Current Assets | 1.82M | 293K | 1.21M | 5.74M | 3.52M | 4.46M | 5.85M |
| Property, Plant & Equipment | 1.39M | 0 | 0 | 5.22M | 3.04M | 4.33M | 1.92M |
| Fixed Asset Turnover | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 867K | 58K | 11K | 0 | 0 |
| Other Non-Current Assets | 422K | 293K | 344K | 455K | 471K | 131K | 3.93M |
| Total Assets | 5.38M▲ 0% | 54.55M▲ 913.8% | 83.75M▲ 53.5% | 131.44M▲ 56.9% | 175.55M▲ 33.6% | 655.68M▲ 273.5% | 734.73M▲ 12.1% |
| Asset Turnover | - | - | - | - | - | - | - |
| Asset Growth % | - | 913.83% | 53.51% | 56.94% | 33.56% | 273.51% | 12.06% |
| Total Current Liabilities | 1.06M | 2.41M | 7.69M | 25.6M | 22.3M | 25.37M | 53.45M |
| Accounts Payable | 342K | 909K | 1.39M | 11.99M | 11.12M | 7.67M | 21.9M |
| Days Payables Outstanding | 245.25 | 1.32K | - | -5.17K | - | - | 17.08K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 549K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 220K | 960K | 377K | 0 | 4.82M | 0 | 31.01M |
| Current Ratio | 3.36x | 22.55x | 10.73x | 4.91x | 7.71x | 25.67x | 13.64x |
| Quick Ratio | 3.36x | 22.55x | 10.73x | 4.91x | 7.71x | 25.67x | 13.64x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 40.87M | 141.5M | 6.47M | 28.93M | 51.56M | 53.16M | 76.76M |
| Long-Term Debt | 0 | 0 | 4.92M | 24.81M | 49.88M | 50.69M | 76.76M |
| Capital Lease Obligations | 10K | 0 | 0 | 3.83M | 1.4M | 2.47M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 40.86M | 141.5M | 1.54M | 286K | 286K | 0 | 0 |
| Total Liabilities | 41.93M | 143.9M | 14.16M | 54.53M | 73.86M | 78.53M | 130.21M |
| Total Debt | 132K | 2K | 4.92M | 31.29M | 53.71M | 54.64M | 77.31M |
| Net Debt | -3.06M | -53.65M | -74.75M | -12.17M | 8.03M | -38.01M | -277.42M |
| Debt / Equity | - | - | 0.07x | 0.41x | 0.53x | 0.09x | 0.13x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -231.41x | -320.76x | -1629.40x | -88.77x | -24.35x | -18.95x | -38.78x |
| Total Equity | -36.55M▲ 0% | -89.35M▼ 144.5% | 69.59M▲ 177.9% | 76.91M▲ 10.5% | 101.69M▲ 32.2% | 577.15M▲ 467.6% | 604.52M▲ 4.7% |
| Equity Growth % | - | -144.47% | 177.89% | 10.51% | 32.22% | 467.59% | 4.74% |
| Book Value per Share | -10.68 | -24.10 | 5.18 | 2.89 | 2.38 | 10.43 | 9.41 |
| Total Shareholders' Equity | -36.55M | -89.35M | 69.59M | 76.91M | 101.69M | 577.15M | 604.52M |
| Common Stock | 0 | 0 | 21K | 28K | 44K | 64K | 71K |
| Retained Earnings | -38.03M | -91.45M | -124.06M | -213.11M | -309.1M | -461.25M | -760.87M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | -224K | 251K | 393K | 786K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VERA Cash Flow Statement
Vera Therapeutics, Inc. (VERA) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -10.29M | -34.81M | -23.71M | -67.6M | -92.18M | -134.68M | -241.1M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -238.31% | 31.89% | -185.12% | -36.37% | -46.1% | -79.02% |
| Net Income | -11.85M | -53.41M | -32.61M | -89.06M | -95.99M | -152.15M | -299.62M |
| Depreciation & Amortization | 509K | 251K | 176K | -846K | -4.09M | 105K | 468K |
| Stock-Based Compensation | 263K | 331K | 3.01M | 8.89M | 11.49M | 20.8M | 37.93M |
| Deferred Taxes | 0 | 0 | -1.8M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 277K | 17.9M | 4M | 6.67M | 2.27M | -6.1M | -2.88M |
| Working Capital Changes | 516K | 123K | 3.51M | 6.75M | -5.87M | 2.66M | 22.99M |
| Change in Receivables | 159K | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -291K | 567K | 475K | 10.61M | -873K | -3.45M | 13.91M |
| Cash from Investing | -125K | -42K | -4.2M | -70.55M | -39.43M | -425.03M | 194.29M |
| Capital Expenditures | -125K | -99K | 0 | -62K | -63K | -972K | -630K |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 796K | 70.49K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 57K | -5M | -70.49K | 0 | 8.97M | -800K |
| Cash from Financing | -137K | 85.29M | 53.88M | 101.93M | 133.54M | 606.67M | 308.9M |
| Debt Issued (Net) | -188K | 5.47M | 4.92M | 19.82M | 24.74M | 0 | 19.82M |
| Equity Issued (Net) | 0 | 80M | 51.18M | 86.13M | 115M | 632.52M | 289.08M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -13K | 0 |
| Other Financing | 51K | -182K | -2.21M | -4.01M | -6.2M | -25.85M | 0 |
| Net Change in Cash | -10.55M▲ 0% | 50.44M▲ 578.0% | 25.97M▼ 48.5% | -36.22M▼ 239.4% | 1.93M▲ 105.3% | 46.97M▲ 2334.7% | 262.08M▲ 458.0% |
| Free Cash Flow | -10.41M▲ 0% | -34.91M▼ 235.2% | -23.71M▲ 32.1% | -67.66M▼ 185.4% | -92.24M▼ 36.3% | -135.65M▼ 47.1% | -241.73M▼ 78.2% |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | -235.2% | 32.08% | -185.38% | -36.34% | -47.06% | -78.2% |
| FCF per Share | -3.04 | -9.41 | -1.76 | -2.55 | -2.16 | -2.45 | -3.76 |
| FCF Conversion (FCF/Net Income) | 0.87x | 0.65x | 0.73x | 0.76x | 0.96x | 0.89x | 0.80x |
| Interest Paid | 51K | 32K | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VERA Key Ratios
Vera Therapeutics, Inc. (VERA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -46.86% | -121.58% | -107.5% | -44.83% | -50.71% |
| Return on Invested Capital (ROIC) | - | - | - | -228.87% | -87.72% | -38.65% | -54.63% |
| Debt / Equity | - | - | 0.07x | 0.41x | 0.53x | 0.09x | 0.13x |
| Interest Coverage | -231.41x | -320.76x | -1629.40x | -88.77x | -24.35x | -18.95x | -38.78x |
| FCF Conversion | 0.87x | 0.65x | 0.73x | 0.76x | 0.96x | 0.89x | 0.80x |
VERA SEC Filings & Documents
Vera Therapeutics, Inc. (VERA) SEC filings — annual & quarterly reports (10-K, 10-Q)
VERA Frequently Asked Questions
Vera Therapeutics, Inc. (VERA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Vera Therapeutics, Inc. (VERA) grew revenue by 0.0% over the past year. Growth has been modest.
Vera Therapeutics, Inc. (VERA) reported a net loss of $299.6M for fiscal year 2025.
Dividend & Returns
Vera Therapeutics, Inc. (VERA) has a return on equity (ROE) of -50.7%. Negative ROE indicates the company is unprofitable.
Vera Therapeutics, Inc. (VERA) had negative free cash flow of $241.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More VERA
Vera Therapeutics, Inc. (VERA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates